# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million d...
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."
Goldman Sachs analyst Chris Shibutani maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50...
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $0.96 per share which missed the analyst consensus estimate of $0.9...
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target fr...
The offering is expected to close on June 10, 2024. Royalty Pharma intends to use the net proceeds from the Notes for general c...